PIK3CA and non-small cell lung carcinoma: Alpelisib (BYL719) is a potent p110α inhibitor, and is currently under investigation in a phase II study of patients with advanced NSCLC and a PIK3CA mutation or amplification.67 INK1117 is another p110α‐specific inhibitor in early phase development.68 Specific p110β inhibitors such as GSK2636771,69 AZD818670 and SAR26030171 have also been tested in phase I trials in patients with advanced solid tumors including NSCLC.